Lutetium (177 Lu) Vipivotide Tetraxetan

Japan-based PeptiDream Inc. (Tokyo Stock Exchange: 4587) has announced the first patient dosing in a first-in-human radiopharmaceutical clinical trial of 64Cu-PD-29875, a macrocyclic peptide conjugate targeting Claudin 18.2 (CLDN18.2) in patients with gastric or gastroesophageal junction (GEJ) cancer. The PeptiDream claudin18.2 radiopharmaceutical program is structured as a Phase 0 imaging study, using copper-64 (⁶⁴Cu) labelling to generate PET/CT imaging data on safety, pharmacokinetics, tumor uptake, and dosimetry. The study’s diagnostic data are intended to inform the development of a companion ²²⁵Ac-labeled therapeutic, forming an integrated radiotheranostic pair. Patient enrollment numbers and a projected completion date were not disclosed. Endpoints center on diagnostic performance characterization and dosimetry, with the imaging data expected to support the design of subsequent therapeutic trials. The program received funding from Japan’s Agency for Medical Research and Development (AMED) under its Practical Research for Innovative Cancer Control initiative in 2024. CLDN18.2 is a tight-junction transmembrane protein whose normal expression is tightly restricted to differentiated gastric epithelial cells, where it remains physically inaccessible to circulating agents. In gastric and GEJ cancer specifically, CLDN18.2 expression is retained through metastatic progression, making it relevant across disease stages rather than only at diagnosis. The clinical validation of this target arrived with the 2024 FDA approval of zolbetuximab-clzb (Vyloy), a CLDN18.2-directed monoclonal antibody from Astellas Pharma, in first-line HER2-negative, CLDN18.2-positive gastric/GEJ adenocarcinoma — the first approved therapy directed at this target. PD-29875 is a macrocyclic peptide discovered using PeptiDream’s proprietary Peptide Discovery Platform System (PDPS) technology and further optimized through in vivo imaging and efficacy studies at PDRadiopharma, PeptiDream’s wholly owned subsidiary. In its diagnostic configuration, the peptide is conjugated to ⁶⁴Cu, a positron emitter with a 12.7-hour half-life suited to the timescale of peptide biodistribution and tumor accumulation. The claudin18.2 PET imaging data generated in this Phase 0 study are designed to confirm tumor uptake, establish dosimetry parameters, and identify patients most likely to benefit from the therapeutic counterpart — a ²²⁵Ac-labeled version of the same peptide scaffold delivering targeted alpha-particle radiation. This theranostic strategy mirrors the PSMA paradigm in prostate cancer, where ⁶⁸Ga-PSMA PET imaging and ¹⁷⁷Lu-PSMA-617 (Pluvicto) therapy operate as a diagnostic-therapeutic pair. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Privacy Terms About Us Copyright © 2026. AllSci Corp. All rights reserved.

The emergence of radiopharmaceuticals represents one of the most significant shifts in modern oncology and diagnostic medicine, potentially moving the field away from blanket treatments toward a highly personalized search and destroy mission at a cellular level. Unlike traditional drugs that may sit on a shelf for months, these are living medical isotopes combined with biological molecules that function as homing beacons, delivering targeted radiation directly to malignant cells while sparing healthy tissue. The very radioactive properties that make them powerful therapies also make them a logistical challenge. In the world of nuclear medicine, radiopharmaceuticals are constantly decaying. For this reason, air transport accounts for a 61.2% share of radiopharmaceutical transport. The moment they are synthesized in a cyclotron or nuclear reactor, a relentless countdown begins. This creates a high-stakes race against the laws of physics, where the therapeutic value of the shipment literally vanishes with every passing hour. Markens mission for nuclear medicine is to deliver these breakthroughs at a targeted time in pristine condition to ensure maximum efficacy. The logistical framework required to move these volatile assets is arguably the most demanding in the entire pharmaceutical sector, characterized by a just-in-time delivery model that leaves absolutely no room for friction. These shipments require high levels of communication and streamlined processes. Beyond the standard rigors of cold-chain management, carriers navigate a complex web of stringent regulatory hurdles, including the Department of Transportation (DOT) Class 7 hazardous materials and international aviation protocols.The transition from general cell and gene therapies to the specific rigors of nuclear medicine highlights a different facet of elevated logistical complexity. While both fields represent the cutting edge of personalized treatment, radiopharmaceuticals introduce the uncompromising element of nuclear physics into the supply chain. Unlike standard regenerative medicines that can often be cryopreserved to pause their biological activity, radioactive isotopes are governed by an immutable physical decay that begins the moment they are synthesized. This creates an environment of extreme time-sensitivity. For radiopharmaceuticals, the logistics is quite literally racing against the atoms themselves. To understand the gravity of this challenge, it takes only a look at the emerging field to see the coordination of several isotopes at once creates a significant logistical puzzle. The transition from traditional, localized medicine to a globally distributed, precision driven model has necessitated a total reimagining of traditional supply chains. While standard pharmaceuticals often benefit from stable shelf lives and forgiving shipping windows, the radiopharmaceutical sector operates under an on-demand reality complicated by the product decay. This shift bridges the gap between the theoretical promise of next generation, personalized therapies and the practical, high-stakes execution required to move active isotopes across continents. To understand the gravity of this challenge, one can simply look at the emergence of new advances.The rise of theranostics, a powerful combination of therapeutics and diagnostics, has further complicated this landscape by integrating two different isotopes into a single patient care plan. This targeted approach typically utilizes a diagnostic isotope, such as gallium-68, to identify tumors via PET scan, followed by a therapeutic isotope like lutetium-177 to deliver the localized radiation. While products like Pluvicto (for prostate cancer) and Lutathera (for neuroendocrine tumors) have revolutionized patient outcomes, they have also doubled the logistical burden. Providers must now synchronize the arrival of two distinct radioactive materials with the patients clinical schedule, ensuring the diagnostics map is created within the timeframe for the therapeutic strike to be administered. The primary difficulty in this supply chain is the half-life of isotopes involved. For example, gallium-68 has a half-life of only about 68 minutes, meaning it loses half of its potency in just over an hour. This narrow window necessitates localized production of the shipment of generators that require specialized handling. Even lutetium-177, which has a more forgiving half-life of roughly 6.7 days, remains highly sensitive to transit times. Any interruption in the white glove delivery service, ranging from heavy traffic to customs holds, can result in the isotope decaying below the required dosage threshold. When the medicine is its own ticking clock, traditional hub-and-spoke distribution models often prove inadequate, requiring dedicated point-to-point couriers instead. Beyond the temporal constraints, the physical requirements for shielding and safety add layers of cost and complexity. Unlike standard biologics, radiopharmaceuticals may require heavy lead or tungsten containers to protect logistics personnel and others from radiation exposure. The weight and dynamics of these containers significantly increase the considerations for each shipment.The value of the packaging also creates a critical return logistics challenge. The expensive, heavy duty transport containers must be tracked, sanitized, and returned to be reused for the next batch. This circular, reverse logistics solution must be managed with the same level of digital visibility as the outbound shipments to avoid bottlenecks anywhere along the supply chain. For patients in remote regions, the distance from a nuclear pharmacy or a major transport hub would typically be a barrier to treatment. The regulatory and infrastructure at international borders also poses a significant challenge to wider accessibility. Every country maintains its own set of rules regarding the transport of Class 7 radioactive materials, and many commercial airlines wont accept radioactive cargo altogether. Markens dedicated experts specializing in Class 7 shipments streamline regulatory compliance and are ready to leverage air and ground resources throughout the UPS network to reach patients worldwide. As the pipeline for nuclear medicine continues to surge, only the pathways built on precision are capable of amplifying growth and carrying the field into the future. '